Preclinical investigations

A new compound reversed four types of chronic pain in animal studies, according to research led by New York University (NYU) College of Dentistry’s Pain Research Center. The small molecule, which binds to an inner region of a calcium channel to indirectly regulate it, outperformed gabapentin without troublesome side effects, providing a promising candidate for […]

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing. Gilead is solely […]

Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace […]

The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval. The EU regulation of the European Medicines Agency (EMA) is also being adapted to mirror the FDA’s regulations. In response, Charles River Laboratories is […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

RNA therapeutics company SiSaf has published positive safety and efficacy data for its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data demonstrate that siRNA complexed with SiSaf’s silicon stabilised hybrid lipid nanoparticles (sshLNP) was able to significantly downregulate expression of an ADO2-specific mutant gene. The company says these results could have significant translational impact on […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

Accurate dose prediction for clinical trials is essential to ensure patient safety and trial success. This new whitepaper from the Jackson Laboratory discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models. In this whitepaper you will learn about: The significance of selecting appropriate starting doses in clinical trials. […]

This whitepaper discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models and emphasises the importance of accurate dose prediction to ensure patient safety and trial success. In this whitepaper you will learn about: The significance of selecting appropriate starting doses in clinical trials. Utilising humanised mouse models […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

A considerable roadblock in the successful triaging of new therapeutics for liver and metabolic related diseases is the reliability and effectiveness of pre-clinical disease models. Methods employing animal models may have limited success in replicating liver diseases, primarily because of species-specific differences, furthermore, the utilisation of animal models to simulate liver disease phenotypes frequently leads […]

In preclinical studies, a new pan-coronavirus papain-like protease (PLpro) inhibitor has shown a near complete reduction in SARS-CoV-2 viral load in the lungs. Infex Therapeutics has selected the clinical candidate for its in-house COV-X programme based on this in vivoefficacy data in a murine SARS-CoV-2 model. The pre-clinical study aimed to assess the efficacy and […]

The results of a preclinical study supporting the antidepressive effects of AlzeCure Pharma’s NeuroRestore ACD856 have been published in the journal Psychopharmacology. The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various preclinical models. The findings are also supported by data […]

With an attrition rate of up to 95% for oncology drug development, it is evident that significant barriers still exist when it comes to translating preclinical investigation findings to in-human trials. This new Guide from TransCure bioServices explores how humanized mouse models can help accelerate the successful development of novel, safe, and effective treatments for oncology […]